Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martel-Pelletier, J
Right arrow Articles by Pelletier, J-P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martel-Pelletier, J
Right arrow Articles by Pelletier, J-P
Annals of the Rheumatic Diseases 2003;62:501-509
© 2003 by BMJ Publishing Group & European League Against Rheumatism

REVIEW

Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs

J Martel-Pelletier , D Lajeunesse , P Reboul , J-P Pelletier

Osteoarthritis Research Unit, Centre hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, Québec H2L 4M1 Canada

Correspondence to:
Correspondence to:
Professor J Martel-Pelletier, Osteoarthritis Research Unit, CHUM, Hôpital Notre-Dame, 1560 rue Sherbrooke Est, Pavillon deSève, Montréal (Québec) H2L 4M1, Canada;
jm{at}martelpelletier.ca


ABSTRACT
Dual 5-LOX/COX inhibitors are potential new drugs to treat inflammation. They act by blocking the formation of both prostaglandins and leucotrienes but do not affect lipoxin formation. Such combined inhibition avoids some of the disadvantages of selective COX-2 inhibitors and spares the gatrointestinal mucosa.

Keywords: cyclo-oxygenase; leucotrienes; 5-lipoxygenase; lipoxin

Abbreviations: AUC, area under the curve; COX, cyclo-oxygenase; FLAP, 5-lipoxygenase activating-protein; GI, gastrointestinal; IL, interleukin; 5-LOX, 5-lipoxygenase; LT, leucotriene; LX, lipoxin; NO, nitric oxide; NSAIDs, non-steroidal anti-inflammatory drugs; PG, prostaglandin; PMN, polymorphonuclear cells; TXA2; thromboxane A2




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
S. Tavolari, M. Bonafe, M. Marini, C. Ferreri, G. Bartolini, E. Brighenti, S. Manara, V. Tomasi, S. Laufer, and T. Guarnieri
Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade
Carcinogenesis, February 1, 2008; 29(2): 371 - 380.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Horrillo, A. Planaguma, A. Gonzalez-Periz, N. Ferre, E. Titos, R. Miquel, M. Lopez-Parra, J. L. Masferrer, V. Arroyo, and J. Claria
Comparative Protection against Liver Inflammation and Fibrosis by a Selective Cyclooxygenase-2 Inhibitor and a Nonredox-Type 5-Lipoxygenase Inhibitor
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 778 - 786.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Vidal, A. Gomez-Hernandez, E. Sanchez-Galan, A. Gonzalez, L. Ortega, J. A. Gomez-Gerique, J. Tunon, and J. Egido
Licofelone, a Balanced Inhibitor of Cyclooxygenase and 5-Lipoxygenase, Reduces Inflammation in a Rabbit Model of Atherosclerosis
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 108 - 116.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 BMJ Publishing Group Ltd & European League Against Rheumatism